Your SOTA was current last year. Is it still valid today?
A manufacturer submitted their clinical evaluation report in February. By June, new cardiovascular guidelines changed the standard of care for their device category. The Notified Body flagged the SOTA section as outdated. The manufacturer argued that nothing about their device had changed. But that was never the point.
In This Article
The state of the art is not a snapshot frozen at the time of submission. It is a moving reference that reflects current medical knowledge, clinical practice, and safety expectations. When clinical guidelines change, your SOTA analysis must follow. Not because the regulation demands constant revision for its own sake, but because the entire clinical evaluation framework depends on comparing your device against what is currently considered best practice.
Most regulatory teams understand this in principle. But in practice, many treat guideline updates as external events that do not trigger internal action unless a Notified Body explicitly requests it. By then, you are already behind.
Why clinical guidelines matter to your SOTA
The state of the art is defined in MDR Article 2(15) as the developed stage of technical capability at a given time. For medical devices, this includes current clinical knowledge, diagnostic methods, and therapeutic options. Clinical guidelines issued by recognized medical societies represent the formalized consensus of that knowledge.
When a guideline changes the recommended diagnostic threshold, treatment pathway, or monitoring protocol, it shifts the reference standard against which your device is evaluated. Your device does not need to change for the SOTA to shift. The clinical context around it has changed.
Here is what I see repeatedly in audits: manufacturers reference guidelines from three or four years ago because that is what was current when the CER was first written. The clinical data section gets updated with new studies. The safety section gets updated with vigilance data. But the SOTA section remains anchored to outdated clinical practice.
The SOTA analysis references clinical guidelines from 2019 while the current version was published in 2023. The manufacturer argues that the device design has not changed, so the SOTA remains valid. The Notified Body disagrees and requests an updated analysis reflecting current clinical practice.
The disconnect comes from treating SOTA as a static technical benchmark rather than a dynamic clinical reference. The device may not have changed, but the medical standard it must meet has evolved.
What triggers the need for a SOTA update
Not every guideline revision requires immediate action. Some updates are administrative or clarify existing recommendations without substantive change. Others fundamentally alter clinical practice. The question is how to distinguish between them and when to act.
A SOTA update is necessary when a guideline change affects one of these areas:
The clinical indication or patient population. If new guidelines refine the population for whom your device type is recommended, or introduce stricter inclusion criteria, your SOTA must reflect that. A device indicated for early-stage disease may now fall outside updated recommendations if guidelines shift toward more advanced presentations.
The standard of care pathway. If your device is positioned as part of a treatment or diagnostic pathway, and that pathway changes, the SOTA must be updated. This includes changes to first-line therapy, recommended sequencing, or monitoring intervals.
Safety thresholds or risk-benefit considerations. Updated guidelines often revise acceptable risk levels based on new evidence. If clinical consensus now considers certain adverse event rates unacceptable, or if new risk factors are identified, your SOTA analysis must address this shift.
Comparator therapies or technologies. Guidelines may introduce new comparators or remove older ones from standard practice. If your clinical evaluation relies on equivalence or comparison to a specific alternative, and that alternative is no longer considered appropriate, the SOTA section needs revision.
The key is this: if the guideline change would alter how a clinician or reviewer interprets the clinical benefit-risk profile of your device, then your SOTA is no longer current.
How often should you review for guideline updates?
There is no regulatory mandate for a specific review frequency, but practical reality suggests at least annually for active devices and whenever major guidelines are published in your clinical domain. Waiting for the next periodic CER update cycle may be too late if guidelines shift significantly in the interim.
Most manufacturers I work with establish a monitoring process where clinical or regulatory affairs staff track publications from relevant medical societies. This does not need to be complex. A quarterly check of key society websites and guideline databases is usually sufficient.
What matters more than frequency is responsiveness. If a major guideline update is published, assess its impact within weeks, not months. Determine whether it changes the SOTA foundation of your CER, and if so, initiate the update process.
The timing of your SOTA update is not about regulatory obligation alone. It is about ensuring that your clinical evaluation framework remains aligned with current medical thinking. A mismatch creates risk during audits and undermines the credibility of your benefit-risk analysis.
How to update the SOTA section effectively
Updating the SOTA is not simply replacing old guideline citations with new ones. It requires reassessing how the updated clinical context affects the interpretation of your device performance and safety data.
Start by documenting what has changed. Identify the specific revisions in the guideline that are relevant to your device. This might be a change in recommended use, a new diagnostic criterion, or updated risk stratification. Be explicit about what shifted and why it matters.
Then, evaluate the impact on your device positioning. Does the updated guideline change where your device fits in the care pathway? Does it introduce new comparators or alter the standard against which your device should be judged? Does it change the expected benefit-risk balance?
This is where many teams stop too early. They update the citations but do not carry the implications forward into the appraisal section of the CER. The SOTA is not a standalone chapter. It is the foundation for the entire clinical evaluation. If the SOTA changes, the appraisal must reflect that change.
For example, if new guidelines lower the acceptable threshold for a specific adverse event, your appraisal must address whether your device data meets this revised threshold. If guidelines now recommend a different monitoring protocol, your PMCF plan may need adjustment to align with current practice.
Documenting the rationale
Notified Bodies and competent authorities will look for clear reasoning, not just updated references. They want to see that you have actively considered the guideline change and assessed its relevance to your device.
This means documenting your decision process. If you determine that a guideline update does not affect your SOTA, explain why. If it does require revision, show how you have integrated the change into your clinical evaluation framework.
A simple statement like
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report).
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
